linjc16/ctgov huggingface dataset:
Research on Oral Tolerability and Product Application/Response of Two Oxalate Products for Dental Patients With Risk of Dentinal Hypersensitivity

Study Overview
=================
Brief Summary
-----------------
This study will assess the oral tolerability and immediate post-treatment safety of topical application for two marketed oxalate products as initial care in dental patients to treat or prevent tooth sensitivity pain that may be attributed to dentinal hypersensitivity.

Conditions
-----------------
Dentinal Hypersensitivity

Intervention / Treatment
-----------------
* Device: Potassium Oxalate Gel
* Device: Potassium Oxalate Liquid
* Drug: Stannous fluoride paste


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be at least 18 years of age sign an informed consent form and be given a copy be in good general health as determined by the Investigator/designee agree to not participate in any other oral care study for the duration of this study agree to return for scheduled visits and follow all study procedures have at least one tooth at risk for hypersensitivity. Exclusion Criteria: any medical condition requiring pre-medication prior to dental procedures any diseases or conditions that might interfere with the subject safely completing the study inability to undergo study procedures a history of kidney stones have self-reported pregnancy or nursing known allergies to the following ingredients; aqua, glycerin, cellulose gum, dipotassium oxalate, carbomer, sodium hydroxide, sodium benzoate, or potassium sorbate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: potassium oxalate gel<br>potassium oxalate gel self applied | Device: Potassium Oxalate Gel<br>* Self applied<br>|
| Other: oxalate liquid, SnF2 paste<br>Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied | Device: Potassium Oxalate Liquid<br>* Professionally Applied<br>Drug: Stannous fluoride paste<br>* SnF2 Paste<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| How Satisfied Were Participants With Treatment? | Questionnaire indicating the frequencies of using various oral hygiene products by subjects at 5 different dental practices. | up to 8 weeks | 
| Ease of Treatment at Home | Questionnaire indicating the frequencies of using various oral hygiene products by subjects at 5 different dental practices. | Up to 8 weeks | 
| Did Participants Notice a Difference in the Areas Noted? | Questionnaire indicating the frequencies of using various oral hygiene products by subjects at 5 different dental practices. | Up to 8 weeks |
Electroacupuncture for Hypertension Patients With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
To observe the Efficiency of Electroacupuncture for Hypertension Patients With Chronic Kidney Disease. To observe if different-time treatment having an impact on Hypertension Patients With Chronic Kidney Disease.

Official Title
-----------------
Electroacupuncture for Hypertension Patients With Chronic Kidney Disease

Conditions
-----------------
HYPERTENSION RENAL

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic kidney disease patients with Hypertension Exclusion Criteria: renal replacement therapy heart failure severe valvular disease sustained arrhythmias secondary hypertension excluded from renovascular hypertension acute cardiovascular events infection

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| morning electroacupuncture with pills<br> | |
| afternoon EA with pills<br> | |
| no EA group with pills<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24 hours Ambulatory Blood Pressure Monitoring Mean arterial pressure change of participants |  | 7 days |
Clinical Database and Biobank of Patients With Gynecologic Neoplasms

Study Overview
=================
Brief Summary
-----------------
The database and biobank establishment started in 1997 in our institute. However, the sample size was too small with respect to our clinical and fundamental scientific research's requirement. Thus the Chinese gynecological oncology study (GOS) group was established to create a large multicentre database and biobank of patients with gynecologic diseases.

Detailed Description
-----------------
The database contains clinical and epidemiologic information about patients with gynecologic neoplasms, such as cervical carcinoma, ovarian carcinoma, etc. With the data gathered from this database, the investigators could further demonstrate the etiology, risk factor, clinical treatment, and other aspects of the complicated gynecologic diseases. The cervical cancer database v1.10 including more than 10,000 cases and more than 200 variables has been established. The biobank collects blood, fluids, tissue samples, and related clinical data from consenting patients with gynecologic neoplasms, such as cervical cancer, ovarian cancer, endometrial cancer, choriocarcinoma, uterine myoma, endometriosis. Besides, blood samples of population-based healthy people with informed consent are also collected.

Official Title
-----------------
A Large Multicentre Clinical Database and Biobank of Patients With Gynecologic Neoplasms

Conditions
-----------------
Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Choriocarcinoma, Uterine Myoma, Endometriosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with informed consent; patients with gynecologic diseases; patients with intact clinical and pathological information Exclusion Criteria: not included in the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gynecologic disease
Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of oral administration of probiotic Lactobacillus rhamnosus GG in middle ear and adenoid tonsil.

Official Title
-----------------
Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil After Randomized, Double-blind, Placebo-controlled Oral Administration

Conditions
-----------------
Upper Respiratory Infection, Acute Otitis Media

Intervention / Treatment
-----------------
* Dietary Supplement: Lactobacillus rhamnosus GG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: recurrent otitis media secretory otitis media chronic rhinitis recurrent sinusitis Exclusion Criteria: significant illness

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lactobacillus rhamnosus GG<br>Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks | Dietary Supplement: Lactobacillus rhamnosus GG<br> <br> |
| Placebo Comparator: Crystalline cellulose<br>Crystalline cellulose | Dietary Supplement: Lactobacillus rhamnosus GG<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lactobacillus Rhamnosus GG in Middle Ear Effusion and Adenoid Tonsil | Presence of Lactobacillus rhamnosus GG in middle ear effusion of children having tympanostomy after oral administration of L. GG. | After 3 weeks of oral consumption | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of Bacterial Pathogens in Middle Ear Effusion Samples | Association of Lactobacillus rhamnosus GG with occurrence of bacterial pathogens in the middle ear. | After 3 weeks of oral consumption | 
| Presence of Rhinovirus and Enterovirus in Middle Ear Effusion Samples | Association of Lactobacillus rhamnosus GG with occurrence of viral pathogens in the middle ear. | After 3 weeks of oral consumption |
Cardiac Injury in Patients With Influenza

Study Overview
=================
Brief Summary
-----------------
This study investigate the prevalence of elevated biomarkers of cardiac injury in patients with suspected influenza infection and the prognostic implication on the composite endpoint of death of any cause, hospitalization due to myocardial infarction, unstable angina, heart failure and stroke.

Detailed Description
-----------------
The relationship between influenza and cardiovascular events was described in an early study of influenza epidemics from 1915 to 1929 including the 1918-1920 pandemic. Retrospective studies have shown increased risk for acute myocardial infarction (AMI) during the first week following an infection with influenza. Biochemical markers of cardiac injury such as high sensitive cardiac troponins may be increased during infection with influenza. Increased levels of cardiac troponins are associated with adverse outcome in many different populations.

Official Title
-----------------
Prevalence and Prognostic Implications of Cardiac Injury in Patients With Influenza-like Illness

Conditions
-----------------
Influenza, Human, Myocardial Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (>18 years) presenting with influenza-like illness. Written informed consent. Exclusion Criteria: Inability to provide informed consent. Age <18 years. Symptoms indicating an acute coronary syndrome, acute heart failure, rapid atrial fibrillation or acute stroke.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of biochemical markers | Level of cardiac troponin in patients with influenza The level of hs-cTn, NT-proBNP and hs-CRP at inclusion in patients with and patientes without influenza. | One year | 
| Level of biochemical markers | Level of other biochemical markers in patients with influenza | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prognostic implication | Time to all-cause death | One year | 
| Prognostic implication | Time to admission for myocardial infarction | One year | 
| Prognostic implication | Time to admission for unstable angina | One year | 
| Prognostic implication | Time to admission for heart failure | One year | 
| Prognostic implication | Time to admission for stroke | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac troponin
Non-Invasive Brain Stimulation to Control Large-Scale Brain Networks

Study Overview
=================
Brief Summary
-----------------
This project will assess the feasibility of traveling wave transcranial alternating current stimulation (tACS) to modify working memory performance and large-scale brain connectivity in surgical epilepsy patients.

Official Title
-----------------
Traveling Wave Transcranial Alternating Current Stimulation for the Control of Large-Scale Brain Networks

Conditions
-----------------
Working Memory

Intervention / Treatment
-----------------
* Device: Transcranial alternating current stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the patient can consent for themselves; the patient has or is scheduled for surgically implanted electrodes for the purposes of phase II epilepsy surgical evaluation; age 18+ years old; Exclusion Criteria: 1. diminished capacity to consent;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stimulation Theta Group<br>Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 4 Hz (theta condition). | Device: Transcranial alternating current stimulation<br>* Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.<br>|
| Experimental: Stimulation Beta Group<br>Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 23 Hz (beta condition). | Device: Transcranial alternating current stimulation<br>* Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Electrophysiological outcomes | Changes in spectral power and coherence of the local field potentials during transcranial electric stimulation relative to no stimulation periods. | Immediate effect during stimulation | 
| Working memory outcomes | Changes in working memory performance as measured with the N-back task (quantified with d-prime) during stimulation. | Immediate effect during stimulation |
Endocannabinoids in End Stage Renal Disease

Study Overview
=================
Brief Summary
-----------------
To investigate the relationship between dietary intake, body habitus, and endocannabinoid levels in end stage renal disease patients as compared to matched controls.

Conditions
-----------------
End Stage Renal Disease, Nutrition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hemodialysis patient, able to give informed consent Exclusion Criteria: hospitalization in past 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| End stage renal disease patient<br> | |
| Matched controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Clinical Epidemiology of Asthma in An HMO

Study Overview
=================
Brief Summary
-----------------
To provide information on morbidity and health care utilization for asthma for a large, well-defined population over a 20 year period.

Detailed Description
-----------------
BACKGROUND: Asthma is the second most common chronic respiratory disorder seen by physicians in outpatients, and in 1988 was estimated to be the primary or secondary cause of 9.3 percent of all physician office visits for ambulatory medical care in the United States. Reports citing increased asthma morbidity and mortality in this country and abroad have intensified interest in this disorder. Investigations into possible explanations for these increases, however, have been hampered by the lack of good longitudinal data on the incidence, prevalence, and health care utilization associated with asthma, and by the lack of generally accepted diagnostic criteria for defining the disease. DESIGN NARRATIVE: Use of the Kaiser-Permanente Northwest Region data base allowed an examination of the secular trends in the prevalence and incidence of physician-diagnosed asthma and asthma-like disorders in inpatient and outpatient populations over a 20 year period, health care utilization and temporal changes in utilization patterns for asthma, and the natural history of asthma in selected subpopulations. Demographic factors examined were limited to age and sex. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Asthma, Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Hypnotic Intake and Motor and Cognitive Performances at High Altitude

Study Overview
=================
Brief Summary
-----------------
This study aims to determine the effect of acute hypnotic intake (Zolpidem) on sleep, cognitive and motor performances and on acute mountain sickness symptoms at high altitude. Healthy subjects will be evaluated on 4 occasions (twice at sea level and twice at high altitude), after hypnotic or placebo intake. Following an early wake-up (01:00), symptoms, cognitive and motor performances will be assessed to determine potential residual effects of Zolpidem within such conditions.

Official Title
-----------------
The Effect of Acute Hypnotic Intake Before a Night at High Altitude on Cognitive and Motor Performances

Conditions
-----------------
Physiology

Intervention / Treatment
-----------------
* Drug: Zolpidem
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No sojourn above 2500 m during the past 2 months Coffee intake < 3 cups per day Non-smoker Exclusion Criteria: Respiratory, cardiovascular, metabolic or neuromuscular diseases Psychiatric disorders Use of hypnotics within the past year Dependence syndrome (alcool, drugs, etc) Severe insomnia or somnolence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Zolpidem Normoxia<br>Acute zolpidem intake at sea level | Drug: Zolpidem<br>* The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.<br>|
| Sham Comparator: Placebo Normoxia<br>Acute placebo intake at sea level | Drug: Placebo<br>* The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.<br>|
| Experimental: Zolpidem Hypoxia<br>Acute zolpidem intake at high altitude | Drug: Zolpidem<br>* The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.<br>|
| Sham Comparator: Placebo Hypoxia<br>Acute placebo intake at high altitude | Drug: Placebo<br>* The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive performance assessed using Simon cognitive test | Simon cognitive test | 4 hours after drug/placebo intake |
Monoamine Oxidases in Smoking Pregnant Women and Newborns

Study Overview
=================
Brief Summary
-----------------
Smoking substantially inhibits the activities of both monamine oxidase (MAO) A and B enzymes. Aims of this study: to compare MAO activities and nicotine and cotinine in peripheral blood of smoking and nonsmoking pregnant women, in their placenta and in cord blood and relate them with the behavior of their newborns being observed during 48 hours after birth.

Detailed Description
-----------------
40 pregnant smoking and 40 pregnant nonsmoking women will be included at the end of the 2nd trimester. Assessments: smoking characteristics, plasma cotinine, DHPG, DOPAC, 5HIAA concentrations reflecting MAOA activity and platelet MAOB activity will be measured just after inclusion (end of 2nd trimester), just before delivery in venous maternal blood and just after delivery in cord blood. The newborns' behavior (wellbeing) will be assessed every 8 hour after birth for 2 days. Comparisons will be made between smoking and nonsmoking women and their newborns.

Official Title
-----------------
Comparison of Monoamines Oxidases A and B Activities and the Metabolism of Nicotine in Smoking and Nonsmoking Pregnant Women and in Their Newborns. Evaluation of Their Effects on the Newborns' Behavior

Conditions
-----------------
Smoking, Pregnancy, Newborn

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnancy of 5 or 6 months nonsmokers: lifetime smoking of less than 100 cigarettes; smokers: unable to stop smoking during the first 3 months of pregnancy; smoking at least 10 cigarettes/day. Exclusion Criteria: pathological pregnancies opioid dependence; alcoholism. chronic psychiatric, hematological, neurological disorders eclampsia chronic antidepressant or neuroleptic treatment current nicotine replacement therapies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pregnant smokers<br> | |
| pregnant non smokers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| monoamine oxidase markers |  | at birth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
smoking, pregnancy, newborns, monoamine oxidases